The 12 best ways to stop the next pandemic | Dr Cassidy Nelson (2020)

Episode Context & Scope

• The episode features Dr. Cassidy Nelson (Oxford FHI) discussing 12 specific policy and career recommendations for pandemic preparedness, aimed at governments and individuals.
• The discussion prioritizes proactive, "pathogen-agnostic" strategies over reactive measures, arguing that current systems are too slow for future outbreaks.
• Nelson notes that 43,000+ NCoV cases had been confirmed globally by mid-February 2020, with the outbreak's growth rate potentially slowing, though undetected cases remain a significant uncertainty.
• Imperial College London estimates less than 10% of actual cases are currently being detected, complicating containment efforts.
• The conversation covers the distinction between "natural" pandemics and "Global Catastrophic Biological Risks" (GCBRs), including accidental lab releases and deliberate bioweapon use.

Current Situation & Containment Feasibility

• Containment of NCoV is likely impossible given the number of cases; the primary goal has shifted to flattening the curve and preventing healthcare system collapse.
• China's response included quarantining over 400,000 contacts and building a 1,000-bed hospital in 10 days, yet case numbers continued to rise, suggesting 19th-century public health isolation tactics may be insufficient for this scale of transmission.
• Travel bans are generally deemed ineffective for rapid respiratory viruses unless implemented at 90-100% closure before local transmission occurs (e.g., island nations).
• Travel bans primarily delay the outbreak peak by roughly three weeks, which is insufficient to develop and manufacture a vaccine (typically 1+ years) but causes significant economic disruption.
• Travel bans create perverse incentives for countries to hide cases to avoid trade sanctions or isolation, reducing global data transparency.

Policy Recommendation 1: Pathogen-Agnostic Diagnostics

• Current PCR testing requires prior knowledge of the pathogen's genetic sequence, creating a 20-day lag in detection for new diseases.
• Metagenomic sequencing (e.g., Nanopore technology) can identify unknown pathogens by sequencing all DNA/RNA in a sample without prior targets.
• Key barriers to adoption include high reagent costs and the need for bioinformatics expertise to interpret data, though costs and accuracy are improving.
• Governments should fund R&D to reduce reagent costs, improve read accuracy, and create incentives (prizes, guaranteed purchase) for companies to deploy these technologies globally.

Policy Recommendation 2: Platform Vaccine Technologies

• Traditional vaccine development takes 10-15 years; the Coalition for Epidemic Preparedness Innovations (CEPI) aims to reduce this to 16 weeks for a candidate and 30 weeks for manufacturing, though these timelines are considered insufficient for high-mortality GCBRs.
• Investment should shift to "platform" technologies (e.g., mRNA, viral vectors) that allow for rapid adaptation to new pathogens once a sequence is identified.
• Current manufacturing relies heavily on chicken eggs, which creates supply chain bottlenecks; alternative cell-based or synthetic production methods are needed.
• Economic models must overcome the "pessimism problem" where pharmaceutical companies lack incentives to fund vaccines that might successfully stop an outbreak before generating sales.

Policy Recommendation 3: Broad-Spectrum Therapeutics

• Unlike antibiotics, broad-spectrum antivirals are difficult to develop because viruses use host cellular machinery, making it hard to target the virus without harming the host.
• Research is needed to identify conserved viral mechanisms or to enhance the host immune response rather than targeting specific viral proteins.
• Funding gaps exist because specific disease-targeted treatments are easier to market and get regulatory approval for than generic "disease X" countermeasures.

Policy Recommendation 4: Generic Pandemic Planning

• Most nations have "Influenza Plans" that are disease-specific and ill-suited for novel pathogens like NCoV, which may lack existing vaccines or treatments.
• Plans must be adaptable to varying transmission rates (R0), incubation periods, and lethality, including triggers for escalating response levels.
• Strategies must account for healthcare system capacity limits; systems are rarely at <95% capacity, leaving no room to absorb a surge of pandemic patients.
• Plans should include alternative care sites (e.g., home isolation with remote monitoring) to prevent nosocomial (hospital-acquired) infections.
• Supply chain resilience is critical, particularly for PPE and essential medicines (e.g., heparin), as global manufacturing hubs (like China) can become bottlenecks during outbreaks.

Policy Recommendation 5: Evidence-Based Travel Bans

• Governments should conduct cost-benefit analyses rather than implementing knee-jerk travel restrictions.
• Bans should only be considered in specific scenarios: pre-local transmission, high lethality, and where economic costs are outweighed by the potential to delay an uncontrollable outbreak.

Policy Recommendation 6: International Data Sharing

• Granular data sharing (onset dates, testing numbers, genomic sequences) is critical for accurate modeling but is often withheld due to fear of economic retaliation (travel/trade bans) or political embarrassment.
• The International Health Regulations (2005) require data sharing with the WHO but lack enforcement mechanisms for transparency.
• Proposals include legal "pre-commitment" frameworks where governments legally bind themselves to share data regardless of political pressure, potentially enforced by international treaties or economic incentives.

Policy Recommendation 7: Environmental Biosurveillance

• Widespread environmental sampling (airports, wildlife interfaces) using metagenomics could detect new pathogens before human cases emerge.
• This faces challenges regarding the "needle in a haystack" problem (false positives) and the technical difficulty of predicting which novel viruses can infect humans.
• Success requires massive infrastructure investment and advanced machine learning to interpret complex data sets, similar to past failed attempts like the US BioWatch program.

Policy Recommendation 8: Laboratory Transparency & Liability

• Incidents involving high-containment labs (BSL-3/4) are rarely reported publicly, hindering the ability to assess and mitigate biosafety risks.
• Increased transparency and mandatory reporting of accidents are necessary, though this creates a disincentive for labs to report minor errors.
• One proposal suggests making labs legally liable for external damages (pandemics caused by accidents), requiring them to purchase insurance, which would price externalities correctly and incentivize safety.

Policy Recommendation 9: DNA Synthesis Screening

• No legal mandate currently exists for screening DNA orders for pathogenic sequences, despite the ability to order dangerous fragments (e.g., smallpox) from private companies.
• Voluntary screening by companies is inconsistent and often limited to long sequences, allowing dangerous fragments to be assembled later.
• Governments should enforce mandatory screening and establish international standards to prevent "shopping" for lax oversight jurisdictions.
• Implementation challenges include protecting the database of dangerous sequences from cyberattacks and managing false positives that delay legitimate research.

Policy Recommendation 10: Dual-Use Research Oversight

• Research with dual-use potential (e.g., making avian flu transmissible or resurrecting horsepox) requires rigorous oversight at the grant, experiment, and publication stages.
• Current review processes often focus on risks to participants rather than risks to the general public ("non-participants").
• A dedicated biosecurity oversight committee is needed to evaluate the net societal benefit of publishing dangerous research, counteracting the "unilateralist" bias toward information availability.

Policy Recommendation 11: Pandemic Tabletop Exercises

• Regular scenario planning exercises (e.g., John Hopkins' "Event 201") are essential to reveal gaps in response plans, resource limits, and misconceptions about timelines (e.g., vaccine speed).
• These exercises should involve senior decision-makers and cross-sector partners (e.g., utilities, private industry) to test coordination and supply chain resilience.
• While exercises can be expensive and subject to criticism (e.g., "predicting" the current outbreak), they are crucial for building institutional memory and buy-in.

Policy Recommendation 12: Coordination & Leadership

• Fragmented biosecurity efforts require centralized coordination, such as a "Biosecurity Leadership Council" to unify government, industry, and academic efforts.
• Specific roles or agencies must be designated to oversee dual-use research and coordinate international responses, preventing issues from being "lost in the ether."
• Without a central coordinating body, policies often fail to be implemented due to siloed responsibilities and lack of accountability.

Career & Individual Actions

• Biosecurity and pandemic preparedness offer diverse career paths in biomedical research, policy analysis, regulatory reform, and scenario planning.
• The "Emerging Leaders in Biosecurity Fellowship" at Johns Hopkins is highlighted as a top-tier pathway for early-career professionals.
• Individuals are advised to maintain personal stockpiles (food, PPE) and prepare for remote work to facilitate social distancing if needed.
• Reusable PPE strategies (e.g., heat sterilization) require further research but represent a significant area for potential impact.

Outlook & Uncertainties

• Nelson remains "cautiously optimistic" that the current crisis will spur investment in proactive measures, citing CEPI's accelerated vaccine targets as a positive signal.
• Technological hurdles (e.g., in silico modeling, nanopore sequencing) are significant but not insurmountable with sufficient funding and political will.
• The "surface area" for impact is vast, spanning government, academia, medicine, and business, allowing for multiple entry points for career contributors.